CION Ameerpet
A brain metastasis from lung cancer is frightening — but it is treatable. Modern focused radiation and brain-penetrant drugs can control lesions and protect how you think, feel and function. CION coordinates every step across our lung and neuro-oncology teams.
When lung cancer cells travel to the brain and start to grow there, doctors call it a brain metastasis — a secondary brain tumour. The brain lesions are still lung cancer under the microscope, not a new brain cancer. This matters, because the treatment is chosen for lung cancer that has spread, not for a tumour that started in the brain.
Lung cancer is the most common cancer to spread to the brain. It happens most often in small cell lung cancer and in certain non-small cell lung cancers (NSCLC) — particularly those driven by EGFR mutations or ALK rearrangements. Sometimes brain spread is found at the very first diagnosis; sometimes it appears months or years later. Either way, there are now real, effective options — and getting the plan right early protects both survival and quality of life. To understand which other cancers behave this way, see our guide on which cancers spread to the brain.
Lung cancer is the single most common source of brain metastases. According to NCCN guidance and EANO consensus on brain metastases, roughly 20–40% of people with lung cancer develop brain spread during their illness — which is why a brain MRI is often recommended at diagnosis for higher-risk lung cancers, even before any symptoms appear.
Many everyday symptoms — an occasional headache, tiredness, forgetfulness — have ordinary causes and are not a sign of brain spread. But if you have known lung cancer, certain new symptoms deserve a prompt brain MRI. The pattern to watch for is a symptom that is new, persistent, and progressive. Red flags include:
Red flag: a first adult seizure, or sudden one-sided weakness or speech loss, needs emergency assessment. For anything new and progressive, speak to a CION specialist about arranging a brain MRI.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have just learned that lung cancer has reached the brain, or want to know if SRS and brain-active drugs are options for you, CION's tumour board is ready — with same-week appointments and transparent costs.
The key test is an MRI of the brain with contrast — the gold standard for finding and characterising brain metastases. MRI shows how many lesions there are, where they sit, how big they are, and how much swelling surrounds them. This information directly shapes the treatment plan. A CT scan is faster and is used in emergencies — for example, a sudden seizure — but MRI is far more sensitive for small lesions.
Just as important is testing the lung cancer itself. If you have not already had full molecular and biomarker testing — EGFR, ALK, ROS1, and PD-L1, among others — this is the moment to make sure it is done. These results tell the team whether a brain-penetrant targeted drug or immunotherapy is an option, and they can change the whole approach. CION arranges this testing and reviews existing reports as part of a lung cancer work-up.
There is no single right answer — the plan depends on how many lesions there are, their size and location, your lung cancer subtype and molecular markers, and how well you feel. CION's tumour board weighs all of this together.
Focused radiation delivered to each lesion from many angles at once — no incision, usually outpatient, in 1 to 5 sessions. For a limited number of metastases, SRS is now the preferred approach in NCCN and EANO guidance because it treats lesions precisely and protects memory and thinking far better than whole-brain radiation.
Radiation to the entire brain still has a role when there are many lesions, or when the lining of the brain (leptomeninges) is involved. It can control widespread disease and relieve symptoms. Because it can affect memory more than SRS, the decision is made carefully and individually.
For a large single lesion causing pressure, or when tissue is needed to confirm the diagnosis, surgery may be recommended. CION does not perform neurosurgery in-house — we coordinate it with accredited neurosurgical partners and manage everything around it, from planning to recovery and follow-up radiation.
For EGFR-mutated or ALK-positive NSCLC, several newer targeted drugs are designed to cross into the brain and can control lesions in many patients. This is delivered by CION's medical oncology team as oral or infusion systemic therapy, chosen from the molecular test results.
For some lung cancers, immunotherapy can help control disease both in the body and, in selected cases, in the brain. Whether it is right for you depends on your subtype, PD-L1 status, and overall plan — decided by the tumour board.
Steroids to reduce brain swelling and anti-seizure medicine when needed are a core part of care. CION also provides rehabilitation, symptom control, and honest support so you and your family always know what to expect next.
One of the most important conversations after a brain metastasis diagnosis is SRS versus whole-brain radiation. For a limited number of lesions, focused SRS is generally preferred because it spares healthy brain and better preserves cognition. Whole-brain radiation is reserved for more widespread disease. If whole-brain radiation has been offered to you without any discussion of SRS, that is a strong reason to seek a second opinion.
Because modern targeted drugs can also shrink brain lesions, the sequence — radiation first, drug first, or both together — is individual. That is exactly the kind of decision a brain tumour treatment team should make together at a tumour board, rather than one specialist deciding alone.
Outcomes for lung cancer brain metastases have improved substantially. EANO and NCCN both now support stereotactic radiosurgery for a limited number of lesions, and for EGFR- and ALK-driven NSCLC, brain-penetrant targeted therapy has changed what is possible — with some patients achieving meaningful, durable control of their brain disease.
Outlook varies widely, and it is important to be honest about that. There is no single survival number for lung cancer brain metastasis — it depends on the lung cancer subtype, molecular markers, the number and size of brain lesions, your symptoms, and general health. Published ranges from sources like SEER and NCCN-linked series describe averages across large groups, not any one person.
What has genuinely changed is that modern SRS and brain-penetrant targeted therapy and immunotherapy have improved outcomes compared with the past — and for patients with driver-mutation NSCLC, some now live well for extended periods with their brain disease controlled. CION discusses prognosis with you personally and sensitively, always as a range and never as a guarantee.
Lung cancer is the most common source of brain metastases, but it is not the only one. Breast cancer, melanoma, and kidney cancer also commonly spread to the brain. If your brain lesions come from a different primary cancer, explore the relevant hub for treatment specific to that cancer:
Not sure where your brain lesions started? Call 18002028726 — our tumour board will review your scans and reports and guide the right next step.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable if your lung cancer has not had full molecular testing, or if whole-brain radiation was offered without discussing SRS.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Lung cancer is the most common cancer to spread to the brain. Around 20–40% of people with lung cancer develop brain metastases at some point, and it is most frequent in small cell lung cancer and in EGFR-mutated or ALK-positive non-small cell lung cancer (NSCLC). Brain spread can be present at diagnosis or appear later. Because the risk is real, many oncologists arrange a brain MRI at diagnosis for higher-risk lung cancers, even without symptoms. Finding lung cancer brain mets early usually means more treatment options and better symptom control.
The most common warning signs are a new or steadily worsening headache (often worse in the morning or on lying down), a first-ever seizure, one-sided weakness or numbness, trouble speaking or finding words, sudden vision changes, unsteadiness, or noticeable changes in memory or personality. Many of these symptoms have ordinary causes. But when you have known lung cancer and a new, persistent, and progressive neurological symptom appears, it should prompt a brain MRI without delay. A first adult seizure is always an emergency.
Yes. Brain metastases are treatable, and treatment can control the disease, relieve symptoms, and protect quality of life. Options include stereotactic radiosurgery (SRS) for a limited number of lesions, whole-brain radiation, neurosurgery (coordinated with accredited neurosurgical partners) for large or single lesions, and modern systemic therapy — targeted drugs for EGFR/ALK-driven NSCLC and immunotherapy — some of which cross into the brain. The right plan depends on how many lesions there are, their size and location, your lung cancer subtype, and how well you feel. CION reviews every case at a tumour board.
For patients with a limited number of brain metastases, SRS is now preferred in most guidelines because it targets each lesion precisely and spares healthy brain — which protects memory and thinking far better than whole-brain radiotherapy. NCCN and EANO both support SRS for limited disease. Whole-brain radiation still has a role when there are many lesions or when the leptomeninges are involved. The decision is individual and is best made by a neuro-oncology tumour board that weighs lesion number, size, location, and your overall condition.
They can. Several modern drugs are designed to reach the brain. For EGFR-mutated NSCLC, newer targeted therapy achieves meaningful control of brain lesions in many patients. For ALK-positive NSCLC, next-generation targeted drugs also have strong activity in the brain. Immunotherapy can help some patients too. This is why molecular and biomarker testing of your lung cancer is essential — it tells the team whether a brain-penetrant drug is an option. CION arranges this testing and coordinates systemic therapy with radiation for the brain.
Outlook varies widely and depends on the lung cancer subtype, molecular markers, the number and size of brain lesions, symptoms, and general health — so there is no single number. Historically, brain metastases carried a poor prognosis, but outcomes have improved substantially with SRS and brain-penetrant targeted therapy and immunotherapy, and some patients with driver-mutation NSCLC now live well for extended periods. Published ranges from SEER and NCCN-linked series are best interpreted for your exact situation. CION frames prognosis honestly and personally — never as a guarantee.
A second opinion is especially valuable here, in three situations: if your lung cancer has not had full molecular/biomarker testing (EGFR, ALK, and others) — this can unlock brain-active drugs; if whole-brain radiation has been offered without discussion of SRS for limited lesions; or if neurosurgery has been advised without a multidisciplinary review. CION offers a free written second opinion. We review your scans and reports, coordinate neurosurgery with accredited partners where needed, and build a plan across our brain tumour and lung cancer teams.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.